Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

CONCLUSION: The neutralizing antibody therapy, BRII-196 plus BRII-198 could shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it didn't show efficacy for improving clinical outcomes among severe or critical cases.PMID:38641625 | PMC:PMC11027409 | DOI:10.1186/s40360-024-00753-7

Source: BMC Pharmacology and Toxicology - April 19, 2024 Category: Drugs & Pharmacology Authors: Qin Yalan Hao Lingfang Liu Xisong Liang Run Zhang Junjing Zhang' An Source Type: research